Welcome to our dedicated page for TScan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.
The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.
TScan Therapeutics, Inc. (TCRX) reports that Amgen has elected to terminate in its entirety their Research Collaboration and License Agreement, which focused on using TScan’s target discovery platform to identify T‑cell antigens in Crohn’s disease. Amgen is exercising a contractual right to terminate with 90 days’ prior written notice, making the termination effective November 10, 2026, and TScan will incur no early termination penalty. TScan had previously received a $30.0 million non‑refundable upfront payment in 2023; the agreement also contemplated more than $500 million in success‑based milestones and tiered single‑digit royalties on future product sales. After termination, TScan does not expect future milestone or royalty payments from this collaboration unless Amgen or its affiliates or sublicensees continue to exploit product candidates, in which case applicable milestones and royalties would survive under the agreement’s terms.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of TScan Therapeutics, Inc. Voting Common Stock. Through Lynx1 Master Fund LP, they jointly report 20,519,148 shares of Voting Common Stock, representing 13.1% of the class, based on 61,074,229 shares outstanding as of May 1, 2026. All reported shares are held with shared voting and dispositive power, and the Lynx1 Fund has the right to receive dividends and sale proceeds from these shares. The filing states it should not be construed as an admission that any Reporting Person is the beneficial owner for all purposes.
Biotechnology Value Fund and affiliates report significant ownership in TScan Therapeutics, Inc. (TCRX). As of June 30, 2026, BVF, BVF2, Trading Fund OS and related entities and a managed account beneficially owned an aggregate of 6,417,831 shares of Voting Common Stock, representing approximately 9.99% of the outstanding shares. This includes Pre-Funded Warrants exercisable for 1,219,288 shares at an exercise price of $0.0001 per share, which do not expire and are subject to a 9.99% beneficial ownership blocker that currently limits exercisability to 853,541 underlying shares. Individually, BVF holds 3,649,002 shares (about 5.7%) and BVF2 holds 2,662,237 shares (about 4.2%), with various BVF general partners and management entities deemed to share voting and dispositive power over these positions.
TScan Therapeutics, Inc. reported continued operating losses and liquidity pressure for the quarter ended June 30, 2026. Collaboration and license revenue was $1.1 million, down from $3.1 million a year earlier, reflecting timing of work under its Amgen collaboration. Research and development expense decreased to $23.4 million from $32.6 million as the company reduced lab spend and headcount after prioritizing its hematologic malignancy programs. General and administrative expense declined modestly to $8.1 million.
Net loss for the quarter was $30.4 million, compared with $37.0 million in the prior-year period. As of June 30, 2026, TScan held $100.2 million in cash and cash equivalents (plus $5.0 million restricted cash) and had an accumulated deficit of $563.9 million. Management states that existing cash is expected to fund operations into the second quarter of 2027, but concludes that substantial doubt exists about the company’s ability to continue as a going concern for 12 months after the financial statements’ issuance.
The company has a $32.5 million term loan outstanding under a Silicon Valley Bank facility, bearing interest at a minimum of 7.00% and subject to a 5% final payment fee. Because TScan did not meet a specified financial milestone by June 30, 2026, interest-only payments will end on September 30, 2026 and principal amortization will accelerate, with the loan now scheduled to mature on September 1, 2028.
TScan Therapeutics, Inc. reported second-quarter 2026 results and updated progress across its pipeline. Revenue was $1.1 million, down from $3.1 million a year earlier, reflecting timing of research activities under its Amgen collaboration. Research and development expenses fell to $23.4 million from $32.6 million, and general and administrative expenses declined to $8.1 million from $9.1 million, contributing to a narrower net loss of $30.4 million versus $37.0 million in the prior-year quarter.
Cash and cash equivalents were $100.2 million as of June 30 2026, and the company believes this will fund its operating plan into the second quarter of 2027. This outlook incorporates commencement of a two-year term-loan amortization beginning in the fourth quarter of 2026 after certain non-covenant milestones under its debt agreement were not achieved by June 30 2026. Common stock and pre-funded warrants outstanding totaled 130,025,962 on June 30 2026.
Operationally, TScan dosed the first patient in its Phase 3 ALLOHA-2™ trial of TSC‑101 in heme malignancies, with topline data expected mid‑2028, and reported positive initial Cohort C data from the Phase 1 ALLOHA™ study, including a ~90% first-pass manufacturing success rate using its commercial-ready process and encouraging donor chimerism responses.
TScan Therapeutics reported positive initial data from Cohort C of its ALLOHA™ Phase 1 study of TSC-101 in patients with blood cancers undergoing allogeneic stem cell transplant. TSC-101, made with a commercial-ready process, led to complete donor chimerism in 11 of 14 patients about three weeks after the first infusion, an early signal linked to lower relapse risk. All but one Cohort C patient (93%) showed decreasing recipient chimerism, indicating effective targeting of residual disease, and no relapses have been observed to date. Safety in Cohort C remained manageable, with fewer acute graft-versus-host disease events than the control group and only one grade 1 cytokine release syndrome event resolving after TSC-101. Earlier ALLOHA data showed 100% of TSC-101–treated patients relapse-free at three years in a small subset versus none on control, helping justify a pivotal Phase 3 ALLOHA-2™ trial targeting relapse-free survival. The company plans to start this Phase 3 trial in Q2 2026 and holds enough cash, $128 as of March 31, 2026, to fund operations into the second half of 2027.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
TScan Therapeutics, Inc. reported an insider Form 4 showing an award of 67,000 non-qualified stock options linked to its common stock. The options were granted to Dr. Stephen R. Biggar, who serves on the board, with a strike price of $0.9946 per share and expiration on May 19, 2036.
The options vest on the earlier of the first anniversary of the May 20, 2026 grant date or the next annual stockholder meeting, subject to Dr. Biggar’s continued board service. Under Baker Bros. Advisors LP policies, Dr. Biggar does not retain economic rights in these securities; related Baker funds instead hold an indirect proportionate pecuniary interest, and Baker-affiliated entities disclaim beneficial ownership beyond that interest.
TScan Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase authorized voting common stock from 300,000,000 to 600,000,000 shares, and the amendment became effective upon filing in Delaware on May 20, 2026.
Katina Dorton and R. Keith Woods were elected as Class II directors to serve until the 2029 annual meeting. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved an adjournment proposal, though adjournment was not needed.
TScan Therapeutics director Keith Woods received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. All 67,000 underlying shares vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options for 67,000 shares directly.
TScan Therapeutics director Garry A. Nicholson received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036. They vest in full on the earlier of May 20, 2027 or the next annual stockholder meeting, subject to his continued service.